Research
Hormonal
GLP-1 receptor agonists have beneficial effects on atherosclerosis and cardiovascular disease.
Practitioners may consider GLP-1 receptor agonists as a treatment option for improving cardiovascular health in patients with obesity and type 2 diabetes.
StrongSupportsmedium confidence
The aim of this review is to summarize available preclinical and clinical data on the beneficial effects of GLP-1 receptor agonists on atherosclerosis and cardiovascular disease.
Why this rating
The claim is based on a review of preclinical and clinical data.
Source
The cardiovascular effects of GLP-1 receptor agonists beyond obesity and type 2 diabetes: An anti-atherosclerotic action
Κλεοπάτρα Αλεξιάδου et al. · Trends in Cardiovascular Medicine · 2024
DOI 10.1016/j.tcm.2024.03.003
reviewCited 23×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →